

# Vincent Launay-Vacher

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5132457/vincent-launay-vacher-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154  
papers

5,070  
citations

37  
h-index

67  
g-index

201  
ext. papers

5,882  
ext. citations

4.3  
avg, IF

5.38  
L-index

#	Paper	IF	Citations
154	Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> ,	4.3	1
153	Antibiotics and chronic kidney disease: Dose adjustment update for infectious disease clinical practice. <i>Médecine Et Maladies Infectieuses</i> , <b>2020</b> , 50, 323-331	4	4
152	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , <b>2019</b> , 96, 555-567	9.9	25
151	Adaptations posologiques chez le patient greffé. <i>Actualites Pharmaceutiques</i> , <b>2019</b> , 58, 31-32	0	
150	Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1522	5.3	4
149	AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 290-290	2.2	
148	Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC) a real-life ambispective study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5540-5540	2.2	
147	Médicaments et insuffisance rénale. <i>Actualites Pharmaceutiques</i> , <b>2018</b> , 57, 33-36	0	1
146	Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , <b>2018</b> , 11, 315-329	4.5	56
145	AUCtox: A new method to evaluate the safety of anticancer drugs.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2534-2534	2.2	
144	Opening an onconephrology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 1503-1510	4.3	26
143	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <i>Journal of Onco-Nephrology</i> , <b>2018</b> , 2, 37-49	0.2	1
142	Anticoagulants in frail patients. Seven situations at risk. <i>JMV-Journal De Medecine Vasculaire</i> , <b>2018</b> , 43, 302-309	0.6	1
141	Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e317-e326	21.7	23
140	A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 128, 78-89	7	10
139	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , <b>2017</b> , 45, 160-169	4.6	220
138	Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2017</b> , 13, 617-623	5.5	3

137	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , <b>2017</b> , 1, 213-219	0.2	
136	Course of chronic kidney disease in French patients. <i>CKJ: Clinical Kidney Journal</i> , <b>2017</b> , 10, 74-78	4.5	
135	Preliminary results of the VENUS study: Bevacizumab efficacy and safety in recurrent, platinum-sensitive ovarian cancer: A real-life ambispective study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e17093-e17093	2.2	
134	Renal insufficiency and cancer treatments. <i>ESMO Open</i> , <b>2016</b> , 1, e000091	6	29
133	Results from the LIDO anemia survey: adherence to EORTC guidelines in cancer patients in France. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 3347-51	3.9	
132	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 245-51	4.5	50
131	Drug-drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacists. <i>Annals of Oncology</i> , <b>2016</b> , 27, 752	10.3	
130	Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2428	2.2	5
129	Renal function and venous thromboembolic diseases. <i>Journal Des Maladies Vasculaires</i> , <b>2016</b> , 41, 389-395		2
128	Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?. <i>AIDS Reviews</i> , <b>2016</b> , 18, 184-192	1.5	28
127	Onco-nephrology: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , <b>2015</b> , 66, 869-83	7.4	31
126	Intermittent dosing of aromatase inhibitors (AI) to improve tolerance in postmenopausal women: a rationale for future clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 653-5	3.5	
125	Anticancer Drugs in End-Stage Kidney Disease Patients. <i>Seminars in Dialysis</i> , <b>2015</b> , 28, 413-6	2.5	6
124	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <i>Annals of Oncology</i> , <b>2015</b> , 26, 1677-84	10.3	52
123	Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. <i>Liver International</i> , <b>2015</b> , 35, 148-55	7.9	30
122	Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists. <i>Targeted Oncology</i> , <b>2015</b> , 10, 199-213	5	36
121	Overall survival in solid tumor patients with abnormal renal function or renal insufficiency.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1589-1589	2.2	4
120	Leaning upon International Directives for Optimization: Anemia Results of the French LIDO anemia survey.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e20739-e20739	2.2	

119	Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16056-e16056	2.2	
118	Leaning upon international directives for optimization: Anemia Results of the French Lidoanemia-2 Survey.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 180-180	2.2	
117	New therapies for hepatitis C: considerations in patients with renal impairment. <i>Drugs</i> , <b>2014</b> , 74, 1307-1321	2.1	4
116	Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients. <i>Cancer</i> , <b>2014</b> , 120, 2158-63	6.4	38
115	Renal insufficiency, mortality, and drug management in heart transplant. Results of the CARIN study. <i>Transplant International</i> , <b>2014</b> , 27, 931-8	3	9
114	Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Néphrogénique Systémique study. <i>Investigative Radiology</i> , <b>2014</b> , 49, 109-15	10.1	52
113	Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2548-2548	2.2	0
112	Results of the MARS study on the management of antiangiogenics—renovascular safety in colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 466-466	2.2	
111	Results of the MARS study on the management of antiangiogenics—renovascular safety in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 394-394	2.2	
110	Malaria prophylaxis in patients with renal impairment: a review. <i>Drug Safety</i> , <b>2013</b> , 36, 83-91	5.1	5
109	An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1361-7	3.5	13
108	Néphrotoxicité des médicaments. <i>Revue Francophone Des Laboratoires</i> , <b>2013</b> , 2013, 75-82	0	3
107	Pulmonary hypertension: use of oral drugs in patients with renal insufficiency. <i>Clinical Drug Investigation</i> , <b>2013</b> , 33, 65-9	3.2	
106	Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 2743-8	3.9	1
105	Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANCer and DialYsis) study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 501-507	10.3	47
104	Results of the MARS study on the management of antiangiogenics—renovascular safety in ovarian cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 5567-5567	2.2	3
103	Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 3033-42	3.9	23
102	Importance of monitoring renal function in patients with cancer. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 235-40	14.4	45

101	European Society of Clinical Pharmacy (ESCP) glossary of scientific terms: a tool for standardizing scientific jargon. <i>International Journal of Clinical Pharmacy</i> , <b>2012</b> , 34, 263-8	2.3	5
100	Colony stimulating factors (CSF) biosimilars. Progress?. <i>Targeted Oncology</i> , <b>2012</b> , 7 Suppl 1, S17-24	5	1
99	Mise à jour des recommandations de la MASCC et de l'ESMO pour la prévention des nausées et vomissements chimio- et radio-induits: résultats de la conférence de consensus de Pérouse. <i>Oncologie</i> , <b>2012</b> , 14, 329-342	1	3
98	Management of antiangiogenics—renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5067-5067	2.2	
97	Management of antiangiogenics—renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1095-1095	2.2	
96	Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 492-4	2.8	14
95	Evaluation of current practice: management of chemotherapy-related toxicities. <i>Anti-Cancer Drugs</i> , <b>2011</b> , 22, 919-25	2.4	12
94	MémoPratic/DHA: guide de prescription pour les voies digestives hautes altées. <i>Oncologie</i> , <b>2011</b> , 13, 116-121	1	0
93	Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 68, 1363-7	3.5	7
92	MémoPratic/DHA*: douleurs et soins de support: guide de prescription pour les voies digestives hautes altées. <i>Douleur Et Analgesie</i> , <b>2011</b> , 24, 56-60	0.2	
91	Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function—the Three-City population-based study. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 2852-9	4.3	64
90	Cancer and renal insufficiency results of the BIRMA study. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 1815-21	8.7	120
89	Toxicité des chélateurs de gadolinium chez le patient insuffisant rénal. <i>Sang Thrombose Vaisseaux</i> , <b>2010</b> , 22, 90-95	3	1
88	Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1395-1403	10.3	112
87	Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. <i>Seminars in Nephrology</i> , <b>2010</b> , 30, 548-56	4.8	57
86	Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study. <i>European Journal of Radiology</i> , <b>2010</b> , 73, 357-9	4.7	37
85	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 124, 745-53	4.4	37
84	Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. <i>Radiology</i> , <b>2009</b> , 250, 618-28	20.5	100

83	Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?. <i>Annals of Oncology</i> , <b>2009</b> , 20, 600-1	10.3	40
82	Drug management of prostate cancer: prevalence and consequences of renal insufficiency. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, E83-9	3.3	19
81	Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. <i>Liver Transplantation</i> , <b>2009</b> , 15, 1083-91	4.5	62
80	Lung cancer and renal insufficiency: prevalence and anticancer drug issues. <i>Lung</i> , <b>2009</b> , 187, 69-74	2.9	34
79	Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. <i>Critical Reviews in Oncology/Hematology</i> , <b>2009</b> , 70, 124-33	7	34
78	Hypertension and proteinuria: a class-effect of antiangiogenic therapies. <i>Anti-Cancer Drugs</i> , <b>2009</b> , 20, 81-2	2.4	80
77	Prescrire les bisphosphonates IV pour la prise en charge des métastases osseuses chez le patient insuffisant rénal. <i>Progrès En Urologie - FMC</i> , <b>2008</b> , 18, F19-F23	0	
76	Comment on: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study: reply. <i>Rheumatology</i> , <b>2008</b> , 47, 1259-1260	3.9	
75	Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer. <i>CKJ: Clinical Kidney Journal</i> , <b>2008</b> , 1, 196-7	4.5	
74	Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4223-5	2.2	13
73	Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. <i>Rheumatology</i> , <b>2008</b> , 47, 350-4	3.9	59
72	Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 903-9	3.5	196
71	Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. <i>Cancer</i> , <b>2007</b> , 110, 1376-84	6.4	293
70	Letter. Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. <i>International Journal of Gynecological Cancer</i> , <b>2007</b> , 17, 1340-1; author reply 1342	3.5	4
69	Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. <i>Annals of Oncology</i> , <b>2007</b> , 18, 1314-21	10.3	110
68	Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 779-84	11.6	34
67	International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 14-34	7.5	198
66	Pharmacokinetics and dosage adjustment of oseltamivir and zanamivir in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , <b>2006</b> , 21, 3606-8	4.3	14

65	Gemcitabine-induced thrombotic microangiopathy: a systematic review. <i>Nephrology Dialysis Transplantation</i> , <b>2006</b> , 21, 3038-45	4.3	95
64	Drug-induced glomerulopathies. <i>Expert Opinion on Drug Safety</i> , <b>2006</b> , 5, 95-106	4.1	20
63	Renal tubular drug transporters. <i>Nephron Physiology</i> , <b>2006</b> , 103, p97-106		88
62	Abnormal blood pressure circadian rhythm: a target organ damage?. <i>International Journal of Cardiology</i> , <b>2006</b> , 107, 343-9	3.2	81
61	FHD: an index to evaluate drug elimination by hemodialysis. <i>American Journal of Nephrology</i> , <b>2005</b> , 25, 342-51	4.6	8
60	Thalidomide for the nephrologist. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 2011-2	4.3	5
59	Drug-induced diabetes mellitus. <i>Expert Opinion on Drug Safety</i> , <b>2005</b> , 4, 1097-109	4.1	26
58	Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. <i>International Journal of Cardiology</i> , <b>2005</b> , 101, 9-17	3.2	52
57	Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. <i>Clinical Pharmacokinetics</i> , <b>2005</b> , 44, 221-35	6.2	21
56	Treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. <i>Journal of Pain</i> , <b>2005</b> , 6, 137-48	5.2	45
55	Fanconi syndrome associated with didanosine therapy. <i>Aids</i> , <b>2005</b> , 19, 844-5	3.5	33
54	Antiretroviral drugs and the kidney: Further precisions. <i>Kidney International</i> , <b>2005</b> , 68, 409	9.9	
53	Thrombocytopenia induced by nicotinamide in hemodialysis patients. <i>Kidney International</i> , <b>2005</b> , 68, 2911-2	9.9	21
52	Immunosuppressive and calcimimetic drug-drug interactions. <i>Kidney International</i> , <b>2005</b> , 68, 1903-4	9.9	1
51	Hepatitis C infection. <i>Kidney International</i> , <b>2005</b> , 68, 2402	9.9	
50	Antiviral drug-induced nephrotoxicity. <i>American Journal of Kidney Diseases</i> , <b>2005</b> , 45, 804-17	7.4	299
49	E.F.P.--European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe. <i>International Journal of Clinical Pharmacy</i> , <b>2005</b> , 27, 278		
48	Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 743-6	4.3	164



47	Viral load and HIV-associated nephropathy. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1072-4	59.2	31
46	Atazanavir: a novel inhibitor of HIV-protease in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , <b>2005</b> , 20, 852-3	4.3	11
45	Antiretroviral drugs and the kidney: further precisions. <i>Kidney International</i> , <b>2005</b> , 68, 409	9.9	1
44	Hepatitis C infection and proteinuria. <i>Kidney International</i> , <b>2005</b> , 68, 2402	9.9	
43	Anemia and diabetes. <i>American Journal of Nephrology</i> , <b>2004</b> , 24, 522-6	4.6	42
42	Hemodialysis and ADAMTS-13. <i>Blood Purification</i> , <b>2004</b> , 22, 480	3.1	
41	Lymphadenopathy and proteinuria. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 739-41	4.3	1
40	Renal safety of tenofovir in HIV treatment-experienced patients. <i>Aids</i> , <b>2004</b> , 18, 1074-6	3.5	133
39	Why is a shrunken bladder and a nephrotic kidney an expression of the same disease?. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 3193-5	4.3	3
38	Ear and kidney syndromes: molecular versus clinical approach. <i>Kidney International</i> , <b>2004</b> , 65, 369-85	9.9	36
37	Antiretroviral and immunosuppressive drug-drug interactions: an update. <i>Kidney International</i> , <b>2004</b> , 66, 532-41	9.9	55
36	Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. <i>Kidney International</i> , <b>2004</b> , 66, 1153-8	9.9	120
35	Epidemiology of microscopic polyarteritis: a 16-year study. <i>Kidney International</i> , <b>2004</b> , 65, 741	9.9	3
34	Using the right MDRD equation. <i>Kidney International</i> , <b>2004</b> , 66, 2089; author reply 2089-90	9.9	4
33	Oculorenal manifestations in systemic autoimmune diseases. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 43, 209-22	7.4	12
32	Doxycycline, gastrointestinal bleeding, and thrombotic microangiopathy. <i>American Journal of Hematology</i> , <b>2004</b> , 77, 319	7.1	28
31	Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 75, 362-3	6.1	9
30	Topiramate-induced renal tubular acidosis. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 281-2	2.4	17



29	Antiretroviral drugs and the kidney: dosage adjustment and renal tolerance. <i>Current Pharmaceutical Design</i> , <b>2004</b> , 10, 4071-9	3.3	8
28	Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. <i>Medical Science Monitor</i> , <b>2004</b> , 10, CR209-12	3.2	31
27	Pharmacokinetics of tenofovir in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , <b>2003</b> , 18, 1931-3	4.3	20
26	Assessing residents' prescribing behavior in renal impairment. <i>International Journal for Quality in Health Care</i> , <b>2003</b> , 15, 235-40	1.9	18
25	Drug-induced Fanconi's syndrome. <i>American Journal of Kidney Diseases</i> , <b>2003</b> , 41, 292-309	7.4	170
24	Inadequacy of antiretroviral drugs dosage adjustment in HIV patients receiving dialysis. <i>Kidney International</i> , <b>2003</b> , 64, 2324	9.9	6
23	Medication misuse in hospitalized patients with renal impairment. <i>International Journal for Quality in Health Care</i> , <b>2003</b> , 15, 331-5	1.9	60
22	Eye and kidney: from clinical findings to genetic explanations. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 516-29	12.7	34
21	Fanconi and inappropriate secretion of antidiuretic hormone syndromes secondary to venlafaxine therapy. <i>Nephron</i> , <b>2002</b> , 92, 944-6	3.3	2
20	Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: case report and review of the literature. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 503-7	6.1	31
19	Pharmacokinetics of tramadol in a hemodialysis patient. <i>Nephron</i> , <b>2002</b> , 92, 755-6	3.3	16
18	Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , <b>2002</b> , 17, 531-2	4.3	5
17	Lymphopenia in Wegener's granulomatosis. A new clinical activity index?. <i>Nephron</i> , <b>2002</b> , 92, 466-71	3.3	12
16	Clinical review: use of vancomycin in haemodialysis patients. <i>Critical Care</i> , <b>2002</b> , 6, 313-6	10.8	50
15	Retroperitoneal fibrosis due to Wegener's granulomatosis: a misdiagnosis as tuberculosis. <i>American Journal of Medicine</i> , <b>2002</b> , 113, 164-6	2.4	26
14	Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study. <i>American Journal of Nephrology</i> , <b>2001</b> , 21, 162-4	4.6	28
13	Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. <i>Nephron</i> , <b>2001</b> , 89, 62-7	3.3	26
12	An appraisal of antiretroviral drugs in hemodialysis. <i>Kidney International</i> , <b>2001</b> , 60, 821-30	9.9	36

11	Pharmacokinetic of nevirapine in haemodialysis. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 192-3	4.3	15
10	Acute pancreatitis induced by isoniazid. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 3208-9	0.7	16
9	Gabapentin neurotoxicity in a chronic haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 2112-3	4.3	20
8	Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient. <i>Nephron</i> , <b>2001</b> , 87, 91-2	3.3	8
7	Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient. <i>Nephron</i> , <b>2001</b> , 87, 186-7	3.3	8
6	Effect of N-acetylcysteine on serum creatinine level. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 1514-1517	4.5	27
5	ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis. <i>Aids</i> , <b>2001</b> , 15, 662-4	3.5	10
4	Baclofen neurotoxicity [correction of unerotoxicity] in a chronic haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , <b>2000</b> , 15, 715-6	4.3	20
3	Dosage of lamivudine in a haemodialysis patient. <i>Nephron</i> , <b>2000</b> , 86, 553	3.3	6
2	Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis. <i>Aids</i> , <b>2000</b> , 14, 618-9	3.5	11
1	Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency. <i>Aids</i> , <b>1999</b> , 13, 1989	3.5	7